logo-loader
viewAlgernon Pharmaceuticals Inc.

Full interview: Algernon Pharmaceuticals receives positive feedback from Health Canada for Ifenprodil

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss the company receiving positive feedback from Health Canada on the Company’s plan for a Phase Two COVID-19 clinical study in Canada, with its repurposed drug Ifenprodil. Moreau explains what that study will look like and he also discusses a similar program in South Korea.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.325 CAD

CSE:AGN
Market: CSE
Market Cap: $29.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: XPhyto sees Germany as key market as they announce deal with...

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers and Bunker, Managing Director Wolfgang Probst joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with German Brewer Oettinger development, production, and distribution of cannabis-infused beverages and...

2 days, 12 hours ago

2 min read